US EditionPublished • loading... • Updated
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Hanmi will supply efpeglenatide and diabetes treatments while Sanfer manages approval and sales; obesity affects 36.86% and diabetes 16.4% of Mexico's population.
- Hanmi Pharmaceutical announced on January 28, 2026, an exclusive distribution deal with Laboratorios Sanfer for efpeglenatide and the Dapalon Family in Mexico, with Hanmi supplying the products and Sanfer handling regulatory approval, marketing, distribution, and sales.
- Mexico's high obesity and diabetes rates underscore demand, with obesity prevalence 36.86% and diabetes prevalence 16.4%, while blood glucose management and healthcare costs drive new therapy needs.
- Hanmi completed its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety on December 17, 2025, and an IND for a Phase 3 trial was approved on January 21, 2026, targeting approval in the second half of 2026 and 2028.
- Sanfer and Hanmi plan phased collaboration to introduce multiple metabolic disease products, aiming to broaden access in Mexico by combining efpeglenatide with Hanmi's diabetes portfolio and addressing blood glucose management over the mid- to long term.
- Operating in more than 20 countries, Laboratorios Sanfer’s recent Probiomed acquisition and in‑house R&D capabilities position it to lead regional rollouts beyond Mexico.
Insights by Ground AI
40 Articles
40 Articles
Coverage Details
Total News Sources40
Leaning Left8Leaning Right3Center11Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 36%
C 50%
14%
Factuality
To view factuality data please Upgrade to Premium
